Comprehensive profiling and molecularly guided therapy (MGT) for carcinomas of unknown primary (CUP): CUPISCO: A phase II, randomised, multicentre study comparing targeted therapy or immunotherapy with standard platinum-based chemotherapy

This is the authors' abstract. We don't add key points for this paper.

Background: CUPs are heterogeneous tumours of diverse origins that often have poor prognoses and high unmet clinical need. Their heterogeneity makes the conduct of clinical trials difficult. The CUPISCO study aims to compare the overall efficacy and safety of MGT with standard platinum-based chemotherapy for patients (pts) with CUP.